Europe Cancer Spit Test Device Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: Europe Cancer Spit Test Device Market

Europe cancer spit test device market is expected to gain significant growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyzes that the Europe cancer spit test device market is growing with a CAGR of 9.3% in the forecast period of 2021 to 2028 and is expected to reach USD 224.29 million by 2028 from USD 115.22 million in 2020. Rising prevalence of chronic diseases and increasing number of cancer patients are the major drivers, which are expected to propel the growth of the market in the forecast period.

A saliva test is nowadays extensively used for cancer detection. A cancer saliva would test for the presence or absence of mutated extra-cellular DNA and RNA. The tumor cells shed DNA and RNA into the circulation and they come into saliva, and mutations are detectable with great accuracy in saliva.

The cancer saliva test devices market comprises testing kits, swabs, cassettes, and devices used for the detection of drugs, infections, or diseases in human beings. Several types of kits utilize different types of molecular biology methods for disease detection. ELISA, PCR, immunoassay, and enzymatic assays among others are molecular techniques that are used for saliva testing.

The Europe cancer spit test device market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.   

The Europe Cancer Spit Test Device Market Scope and Market Size

The Europe cancer spit test device market is segmented on the basis of product type, site of collection, application, age group, method of collection, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of product type, the Europe cancer spit test devices market is segmented into saliva collection kits, fluid specific devices, oral swab, bar-code labels, saliva cryostorage box, and others.  In 2021, saliva collection kits segment is expected to dominate the market due to increasing pool of cancer patients in the region.
• On the basis of site of collection, the Europe cancer spit test devices market is segmented into sub-mandibular/sub-lingual gland, parotid gland, and minor salivary gland. In 2021, sub-mandibular/sub-lingual gland segment is expected to dominate the market owing to increasing healthcare expenditure and growing awareness among people about cancer.
• On the basis of application, the Europe cancer spit test devices market is segmented into liver-lung cancer, breast cancer, colon and rectal cancer, prostate cancer, pancreatic cancer, oral cancer, thyroid cancer, endometrial cancer, kidney cancer, leukemia, melanoma, non-hodgkin lymphoma, and others. In 2021, liver-lung cancer segment is expected to dominate the market owing to excessive smoking among people and rising prevalence of liver cirrhosis.
• On the basis of age group, the Europe cancer spit test devices market is segmented into adult and pediatrics. In 2021, adult segment is expected to dominate the market owing to surging pool of geriatric population and increasing prevalence chronic diseases in the region.
• On the basis of method of collection, the Europe cancer spit test devices market is segmented into passive drool, oral swab, and others. In 2021, passive drool segment is expected to dominate the market owing to its non-invasive method with better patient compliance.
• On the basis of end user, the Europe cancer spit test devices market is segmented into hospitals, diagnostic laboratories, oncology specialty clinics, cancer research institutes, and others. In 2021, hospitals segment is expected to dominate the market owing to surging volume of cancer patients and better treatment options for different types of cancer.
• On the basis of distribution channel, the Europe cancer spit test devices market is segmented into direct tender, retail sales, and others. In 2021, direct sales segment is expected to dominate the market owing to growing presence of major players in the market.

Europe Cancer Spit Test Devices Market Country Level Analysis

The Europe cancer spit test devices market is analyzed and market size information is provided based on product type, site of collection, application, age group, method of collection, end user, and distribution channel.

Countries covered in the Europe cancer spit test device market report are Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Austria, Sweden, Belgium, Estonia, and Rest of Europe. The market in Europe is expected to grow significantly in the forecast period of 2021 to 2028 due to increasing technological advancements in the region. Germany is dominating the European market owing to growing presence of key players in the market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Healthcare Expenditure and High Prevalence of Cancer are Creating New Opportunities for Players in the Europe cancer spit test devices market

Germany is leading the growth of Europe region and saliva collection kits segment is dominating the country due to rising demand for POCT devices.

Europe cancer spit test devices market also provides you with detailed market analysis for every country growth in particular industry with the Europe cancer spit test device market sales, impact of advancement in the Europe cancer spit test device market and changes in regulatory scenarios with their support for the Europe cancer spit test devices market. The data is available for historic period 2010 to 2018. 

Competitive Landscape and Europe Cancer Spit Test Device Market Share Analysis

Europe cancer spit test device market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to Europe cancer spit test devices market.

Major players covered in the report are DNA Genotek, Salimetrics, LLC, PeriRx, Color Health, Inc., SARSTEDT AG. Co. KG,  Miraclean Technology Co., Ltd.,  Agilent Technologies, Inc., Illumina, Inc., QIAGEN, Thermo Fisher Scientific Inc., Abbott, BD, Biocartis, bioMérieux SA, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd,  Oasis Diagnostics Corporation, and Canvax ( a subsidiary of dobuss) among other domestic and Europe players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies worldwide, which are further accelerating the growth of the Europe cancer spit test device market.

For instance,

• In February 2021, Thermo Fisher Scientific was recognized with six CMO Leadership Awards. It won across all six categories, including capabilities, compatibility, expertise, quality, reliability, and service. This is the second consecutive year Thermo Fisher has received this recognition across all six categories and the eighth time overall that the company has been honored by the CMO Leadership Awards. This has increased the credibility of the company and aided in revenue generation.
• In January 2021, DNA Genotek announced that the U.S. Food and Drug Administration (FDA) has granted a general use 510(k) clearance for its OrageneDx family of products. This FDA approval has increased the credibility of the company in the market and increased the demand for this product.

SKU-64145